Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230109 · ClinicalTrials.gov registry record · Phase 2
Sacituzumab Govitecan In TNBC
A Phase 2 study of Triple Negative Breast Cancer and HER2-Negative Breast Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
- 5
- Study locations
NCT04230109: Recruiting Phase 2 study of Triple Negative Breast Cancer and HER2-Negative Breast Cancer, sponsored by Massachusetts General Hospital.
NCT04230109 is a Phase 2 study of Triple Negative Breast Cancer and HER2-Negative Breast Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 260 participants, roughly in line with the 244-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target. The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230109, a Phase 2 study of Triple Negative Breast Cancer and HER2-Negative Breast Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Primary Outcome
pCR is defined as no residual invasive carcinoma in the breast and in the lymph node. The two-sided 95% CIs for pCR rate will be calculated.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Sacituzumab Govitecan
Study Locations (5)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- Massachusetts General Hospital - North Shore Cancer Center - Danvers
- Massachusetts General Hospital at Newton-Wellesley Hospital - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
What NCT04230109 shows while recruiting
NCT04230109 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 244-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target.
The record links to 5 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04230109 lists 5 locations in 1 state (Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04230109 about?
NCT04230109 is a clinical study titled "Sacituzumab Govitecan In TNBC". This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
What is the current status of trial NCT04230109?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2020-07-14. Estimated completion is 2029-10.
What conditions does trial NCT04230109 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, HER2-Negative Breast Cancer, Invasive Breast Cancer, ER-negative Breast Cancer, PR-Negative Breast Cancer.
What interventions are being tested in trial NCT04230109?
The interventions under investigation include: Pembrolizumab (DRUG), Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT04230109?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04230109 being conducted?
This trial has 5 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04230109's enrollment target sits among peer trials
260 24th of 118 higher than 94 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI